Clinical Trial

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Study acronym: MOVE
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2025-11-04.
Status change: Not Yet Recruiting → Recruiting 2025-08-01
Trial Details
NCT Number NCT07075471
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Tenosynovial Giant Cell Tumor
Enrollment 100 participants
Start Date 2025-09-03
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-27